These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 35969402)

  • 1. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
    Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
    JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
    O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
    JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
    McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
    JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
    Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
    JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
    Isa F; Gonzalez Ortiz AM; Meyer J; Hamilton JD; Olenchock BA; Brackin T; Ganguly S; Forleo-Neto E; Faria L; Heirman I; Marovich M; Hutter J; Polakowski L; Irvin SC; Thakur M; Hooper AT; Baum A; Petro CD; Fakih FA; McElrath MJ; De Rosa SC; Cohen KW; Williams LD; Hellman CA; Odeh AJ; Patel AH; Tomaras GD; Geba GP; Kyratsous CA; Musser B; Yancopoulos GD; Herman GA;
    Lancet Infect Dis; 2024 Sep; ():. PubMed ID: 39236733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
    Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Xiao J; Hooper AT; Hamilton JD; Musser BJ; Rofail D; Hussein M; Im J; Atmodjo DY; Perry C; Pan C; Mahmood A; Hosain R; Davis JD; Turner KC; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Roque-Guerrero L; Acloque G; Aazami H; Cannon K; Simón-Campos JA; Bocchini JA; Kowal B; DiCioccio AT; Soo Y; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
    N Engl J Med; 2021 Dec; 385(23):e81. PubMed ID: 34587383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
    Somersan-Karakaya S; Mylonakis E; Menon VP; Wells JC; Ali S; Sivapalasingam S; Sun Y; Bhore R; Mei J; Miller J; Cupelli L; Forleo-Neto E; Hooper AT; Hamilton JD; Pan C; Pham V; Zhao Y; Hosain R; Mahmood A; Davis JD; Turner KC; Kim Y; Cook A; Kowal B; Soo Y; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
    J Infect Dis; 2022 Dec; 227(1):23-34. PubMed ID: 35895508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
    O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
    medRxiv; 2021 Sep; ():. PubMed ID: 34159343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
    Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
    Herman GA; O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Musser BJ; Davis JD; Turner KC; Mahmood A; Hooper AT; Hamilton JD; Parrino J; Subramaniam D; Baum A; Kyratsous CA; DiCioccio AT; Stahl N; Braunstein N; Yancopoulos GD; Weinreich DM;
    Lancet Infect Dis; 2022 Oct; 22(10):1444-1454. PubMed ID: 35803290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
    Isa F; Forleo-Neto E; Meyer J; Zheng W; Rasmussen S; Armas D; Oshita M; Brinson C; Folkerth S; Faria L; Heirman I; Sarkar N; Musser BJ; Bansal S; O'Brien MP; Turner KC; Ganguly S; Mahmood A; Dupljak A; Hooper AT; Hamilton JD; Kim Y; Kowal B; Soo Y; Geba GP; Lipsich L; Braunstein N; Yancopoulos GD; Weinreich DM; Herman GA;
    Int J Infect Dis; 2022 Sep; 122():585-592. PubMed ID: 35788416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
    Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
    J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
    J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
    Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
    Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
    J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
    O'Brien MP; Forleo-Neto E; Musser BJ; Isa F; Chan KC; Sarkar N; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Hou P; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
    N Engl J Med; 2021 Sep; 385(13):1184-1195. PubMed ID: 34347950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.
    Hooper AT; Somersan-Karakaya S; McCarthy SE; Mylonakis E; Ali S; Mei J; Bhore R; Mahmood A; Geba GP; Dakin P; Weinreich DM; Yancopoulos GD; Herman GA; Hamilton JD;
    mBio; 2022 Dec; 13(6):e0169922. PubMed ID: 36255239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.